Compare Heron Therapeutics Inc (HRTX) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Stanley Black & Decker, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Stanley Black & Decker, Inc. trades at $102.49 (market cap $15.71B). The key difference: Stanley Black & Decker, Inc. is far larger — about 255.6× Heron Therapeutics Inc's market cap, and Stanley Black & Decker, Inc. pays a 3.23% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | SWK | |
|---|---|---|
Market Cap | $61.47M | $15.71B |
Sector | Health | — |
52-Week High | $1.49 | $104.00 |
52-Week Low | $0.32 | $62.12 |
Enterprise Value | $168.21M | $19.87B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
Stanley Black & Decker (SWK) trades at $102.64, down 1.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations with EPS of $1.57 versus $1.21 expected, driven by margin expansion and strong organic growth. The company announced a $1 billion U.S. investment plan to boost manufacturing and innovation, signaling strategic growth commitment.
The outlook is positive with improving profitability and debt reduction, but risks include competitive pressures and economic sensitivity. Analysts are mixed with a $93.67 consensus target below current price, suggesting cautious optimism. Upside hinges on continued execution of cost savings and market share gains in tools and infrastructure sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
